FDA Approves Adstiladrin, Gene Therapy for Tough-to-Treat Bladder Cancer

MONDAY, Dec. 19, 2022 -- The U.S. Food and Drug Administration on Friday approved a gene therapy called Adstiladrin (nadofaragene firadenovec-vncg), which is designed to work for patients with high-risk non-muscle-invasive bladder cancer (NMIBC)...